# US 2013/0157260 A1 · Identification of compounds that regulate apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157260 A1
- Document ID: US20130157260A1
- Status: Published application
- Kind: A1
- Application number: 12/959,054
- Filed: 2010-12-02
- Published: 2013-06-20
- Earliest claimed: 2005-05-12
- Assignees: Sanford-Burnham Medical Research Institute
- Inventors: Arnold Satterthwait; Xiao-kun Zhang; Xiuwen Zhu; Siva Kolluri; John C. Reed
- Web page: https://patentgrep.com/patent/US20130157260A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61P 35/00: Antineoplastic agents
- C07K 14/4747: {Apoptosis related proteins}
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An assay for identifying compounds that affect conversion of Bcl-2 family protein from an antiapoptotic to a proapoptotic form or inhibit activity of Bcl-2 family protein is described.

## Claims

### Claim 1

A method of screening for compounds capable of converting a Bcl-2 family protein from an antiapoptotic form to a proapoptotic form, comprising:
providing a Bcl-2 family protein;
providing a fluorescently labeled compound known to bind to and convert said Bcl-2 family protein to a proapoptotic form;
contacting said Bcl-2 family protein and said fluorescently labeled compound in the presence or absence of a test compound; and
determining fluorescence of said Bcl-2 family protein, wherein a decrease in fluorescence indicates that said test compound is capable of converting said Bcl-2 family protein from an antiapoptotic form to a proapoptotic form.

### Claim 2 (depends on 1)

The method of claim 1, wherein said test compound is a natural product or natural product derivative.

### Claim 3 (depends on 1)

The method of claim 1, wherein said test compound is a peptidomimetic.

### Claim 4 (depends on 1)

The method of claim 1, wherein said test compound is a small molecule.

### Claim 5 (depends on 1)

The method of claim 1, wherein said test compound is a Nur77 peptide.

### Claim 6 (depends on 5)

The method of claim 5, wherein said Nur77 peptide is NuBCP-9.

### Claim 7 (depends on 5)

The method of claim 5, wherein said Nur77 peptide is D-NuBCP-9.

### Claim 8 (depends on 1)

The method of claim 1, wherein said fluorescent label is Fluorescein.

### Claim 9 (depends on 1)

The method of claim 1, wherein said fluorescent label is Green Fluorescent Protein (GFP).

### Claim 10 (depends on 1)

The method of claim 1, wherein said fluorescently labeled compound is a Nur77 peptide.

### Claim 11 (depends on 10)

The method of claim 10, wherein said Nur77 peptide is NuBCP-9-r8 peptide.

### Claim 12 (depends on 1)

The method of claim 1, wherein said Bcl-2 family protein is Bcl-2.

### Claim 13 (depends on 1)

The method of claim 1, wherein said Bcl-2 family protein is Bcl-B.

### Claim 14 (depends on 1)

The method of claim 1, wherein said Bcl-2 family protein is Bfl-1.

### Claim 15 (depends on 1)

The method of claim 1, further comprising at least one secondary screen to confirm that said test compound converts said Bcl-2 family protein from an antiapoptotic to a proapoptotic form.

### Claim 16 (depends on 15)

The method of claim 15, wherein said secondary screen is an apoptosis assay.

### Claim 17 (depends on 16)

The method of claim 16, wherein said apoptosis assay is selected from the group consisting of staining annexin-v, detecting caspase activity, and detecting DNA fragmentation.

### Claim 18 (depends on 1)

The method of claim 1, wherein said fluorescence is measured by fluorescence polarization.

### Claim 19

A method of screening for compounds capable of inhibiting a Bcl-2 family protein, comprising:
providing a Bcl-2 family protein;
providing a fluorescently labeled compound known to bind to said Bcl-2 family protein;
contacting said Bcl-2 family protein and said fluorescently labeled compound in the presence or absence of a test compound; and
determining fluorescence of said Bcl-2 family protein, wherein a decrease in fluorescence indicates that said test compound is capable of inhibiting said Bcl-2 family protein.

### Claim 20 (depends on 19)

The method of claim 19, wherein said test compound is a Nur77 peptide.

### Claim 21 (depends on 20)

The method of claim 20, wherein said Nur77 peptide is NuBCP-9.

### Claim 22 (depends on 20)

The method of claim 20, wherein said Nur77 peptide is D-NuBCP-9.

### Claim 23 (depends on 19)

The method of claim 19, wherein said fluorescent label is Fluorescein or Green Fluorescent Protein (GFP).

### Claim 24 (depends on 19)

The method of claim 19, wherein said fluorescently labeled compound is a Nur77 peptide.

### Claim 25 (depends on 24)

The method of claim 24, wherein said Nur77 peptide is NuBCP-9-r8 peptide.

### Claim 26 (depends on 19)

The method of claim 19, wherein said Bcl-2 family protein is Bcl-2, Bcl-B, or Bfl-1.
